Arab Finance: Minapharm Pharmaceuticals (Minapharm) (MIPH) reduced its standalone net loss after tax by 71.5% in the first half (H1) of 2022 to EGP 43.64 million from EGP 52.81 million in H1 2021, according to the standalone financial statement filed to the Egyptian Exchange (EGX) on August 11^th.

Net sales amounted to EGP 1.10 billion in H1 2022, up from EGP 1.02 billion in the same period last year.

Minapharm Pharmaceuticals is an Egypt-based company engaged in the production and distribution of pharmaceutical products. It is in cooperation with several international pharmaceutical companies and it distributes its products within and outside Egypt.